TribLIVE

| Business

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Bayer AG earnings up 7.7% during 3Q

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Staff and Wire Reports
Thursday, Oct. 31, 2013, 11:03 a.m.
 

Bayer AG's third-quarter earnings rose 7.7 percent on higher sales for a new blood thinner and eye treatment that are recharging its drug portfolio.

Operating profit rose to $2.7 billion from $2.5 billion a year earlier, the Leverkusen, Germany-based parent of Bayer Corp. in Robinson said on Thursday. That beat the $2.55 billion average estimate of 11 analysts surveyed by Bloomberg.

New medicines, including the blood thinner Xarelto and the eye drug Eylea, have helped drive Bayer's profit upward even as earnings from its MaterialScience plastics division lag. Bayer is in talks with workers to cut costs at the unit, which makes chemicals for everything from makeup to car parts, CEO Marijn Dekkers told reporters in September.

“People do want to own this for the pharma growth,” said Fabian Wenner, an analyst for Kepler Cheuvreux in Zurich. “Investors don't really care about 2013 anymore.” Wenner rates the stock a hold.

Third-quarter sales fell 0.2 percent to $13.1 billion, below the average analyst estimate of $13.3 billion.

Bayer Corp.'s operations in North America had $2.83 billion in sales, down 3.6 percent from a year ago. For the first nine months of the year, sales were $9.94 billion, up 1.4 percent compared to the same period in 2012. Bayer has 15,400 employees in North America, including 2,300 in the Pittsburgh region, the largest of 50 Bayer sites in the United States.

Bloomberg News and Trib Total Media staff writer John D. Oravecz contributed to this report. He can be reached at 412-320-7882 or joravecz@tribweb.com.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Small business hangs on fate of Export-Import Bank
  2. $2-per-gallon gas expected by year’s end, but not in Western Pa.
  3. FirstEnergy to build coal waste processing facility in Beaver County
  4. Muni bond funds stressed
  5. Chevy tweaks its truck remake
  6. Jaguar XJ flagship struggles to keep pace
  7. Trib 30 index slips in July; 29 percent drop makes ATI biggest loser
  8. 3 vehicles to keep an eye on for 2016
  9. Insurers: F-150’s aluminum costly to repair
  10. Wages, benefits stagnant, U.S. says
  11. Low fuel pressure may have easy fix